Chiu SN, et al. - This multicenter study was performed to examine the efficacy of a novel palivizumab protocol for hemodynamically significant congenital heart disease (hsCHD) in subtropical areas without clear respiratory syncytial virus seasonality. Among patients with hsCHD, palivizumab prophylaxis through the novel monthly protocol was found to be effective in reducing respiratory syncytial virus-related hospitalizations.